AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15580062 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in carbohydrate
Number of subjects: 20
Study 15580062 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in protein
Number of subjects: 20
Study 15580062 — intervention group
Group type: COMPARATOR
Intervention: Fasting exercise test
Number of subjects: 20
Study 11298548 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg daily (n = 30)
Number of subjects: 60
Study 11298548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (moisturizing ointment) (n = 30)
Number of subjects: 60
Study 11233189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker (DDD) treatment
Number of subjects: 83
Study 11233189 — intervention group
Group type: COMPARATOR
Intervention: Sham phase
Number of subjects: 83
Study 8003095 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS levels in cases
Number of subjects: 159
Study 8003095 — intervention group
Group type: COMPARATOR
Intervention: DHEAS levels
Number of subjects: 159
Study 2573727 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 6
Study 2573727 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 6
Study 4817683 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy supervised by a physiotherapist
Number of subjects: 96
Study 4817683 — intervention group
Group type: COMPARATOR
Intervention: Mobilization headed by a physician with written and oral instructions
Number of subjects: 96
Study 29550650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 W/kg (Low RF)
Number of subjects: 36
Study 29550650 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 W/kg (High RF)
Number of subjects: 36
Study 29550650 — intervention group
Group type: COMPARATOR
Intervention: 0 W/kg (Sham)
Number of subjects: 36
Study 24515943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri 10^8 organisms once daily for 5 days
Number of subjects: 45
Study 24515943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing)
Number of subjects: 45
Study 20661272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 331
Study 20976769 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (daily folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Number of subjects: 273
Study 20976769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 19156097 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bascom method
Number of subjects: 96
Study 19156097 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of coccygeal duct excision and wound closure
Number of subjects: 96
Study 15722810 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (rheumatologist and physical therapist intake and discharge, 18 group supervised exercise therapy sessions, 2 group pain and stress management lectures, 1 group education lecture, 1 group dietary lecture, and 2 massage therapy sessions)
Number of subjects: 79
Study 15722810 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care with the patients' family physician
Number of subjects: 79
Study 12535870 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 12535870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 15
Study 12535870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10566672 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet for 16 weeks followed by a hypocaloric diet for 32 weeks
Number of subjects: 69
Study 10566672 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial leptin levels and large declines in serum leptin
Number of subjects: 69
Study 10566672 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels (baseline or changes)
Number of subjects: 69
Study 2193627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day doxycycline regimen
Number of subjects: 59
Study 2193627 — intervention group
Group type: COMPARATOR
Intervention: 5-day josamycin regimen
Number of subjects: 59
Study 341689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrogastrone (carbenoxolone sodium with alginate antacid) for 8 weeks
Number of subjects: 37
Study 341689 — intervention group
Group type: COMPARATOR
Intervention: Control (alginate antacid alone, Gaviscon‐like)
Number of subjects: 37
Study 31981106 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02%/latanoprost 0.005% fixed combination QD for 3 months
Number of subjects: 415
Study 31981106 — intervention group
Group type: COMPARATOR
Intervention: Netarsudil 0.02%
Number of subjects: 415
Study 31981106 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 415
Study 31142366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 100
Study 31142366 — intervention group
Group type: COMPARATOR
Intervention: Social Interaction and Routine Education (SIRE)
Number of subjects: 100
Study 28808942 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-sensitive alerts delivered to PCPs' InBaskets
Number of subjects: 799
Study 28808942 — intervention group
Group type: EXPERIMENTAL
Intervention: Alerts for patients with longer hospital stays (>4 days)
Number of subjects: 799
Study 28808942 — intervention group
Group type: COMPARATOR
Intervention: Alerts delivered to PCPs with a higher number of notifications at the time of alert delivery
Number of subjects: 799
Study 28808942 — intervention group
Group type: COMPARATOR
Intervention: Alerts delivered on Saturdays
Number of subjects: 799
Study 26537175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention based on cognitive behavioral and mindfulness principles
Number of subjects: 0
Study 26537175 — intervention group
Group type: COMPARATOR
Intervention: Active control condition teaching study skills
Number of subjects: 0
Study 25747685 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic consent group (n = 32)
Number of subjects: 62
Study 25747685 — intervention group
Group type: COMPARATOR
Intervention: Paper-based consent group (n = 30)
Number of subjects: 62
Study 23071195 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT(®)LOUD with Companion
Number of subjects: 16
Study 23071195 — intervention group
Group type: COMPARATOR
Intervention: Historical treatment group with standard, in-person LSVT LOUD
Number of subjects: 16
Study 18713796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray treatment with Streptococcus sanguinis
Number of subjects: 60
Study 18713796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray treatment with Lactobacillus rhamnosus
Number of subjects: 60
Study 18713796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17505041 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BVP-ON)
Number of subjects: 239
Study 17505041 — intervention group
Group type: COMPARATOR
Intervention: Control group (BVP-OFF)
Number of subjects: 239
Study 15240654 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 lux light stimulus for 6.5 hours after prior exposure to 0.5 lux
Number of subjects: 8
Study 15240654 — intervention group
Group type: COMPARATOR
Intervention: 200 lux light stimulus for 6.5 hours after prior exposure to 200 lux
Number of subjects: 8
Study 12074774 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1077
Study 9819038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) continuous infusion
Number of subjects: 0
Study 9819038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with heparin
Number of subjects: 0
Study 9819038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with low‐molecular‐weight heparin (LMWH, enoxaparin)
Number of subjects: 0
Study 9819038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) with saline solution
Number of subjects: 0
Study 9819038 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) continuous infusion systems
Number of subjects: 0
Study 7806134 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 p.m.
Number of subjects: 24
Study 7806134 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 a.m.
Number of subjects: 24
Study 2595041 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticare 500
Number of subjects: 100
Study 2595041 — intervention group
Group type: EXPERIMENTAL
Intervention: Novametrix 500
Number of subjects: 100
Study 2595041 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual display
Number of subjects: 100
Study 6778331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulverized prednisone tablets (5 mg)
Number of subjects: 41
Study 6778331 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant sulfisoxazole suspension of 50 mg/kg/day twice daily
Number of subjects: 41
Study 6778331 — intervention group
Group type: COMPARATOR
Intervention: Lactose powder (placebo)
Number of subjects: 41
Study 30991720 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofrito (240 g/70 kg)
Number of subjects: 22
Study 28391599 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stop-shop with in vivo reflectance confocal microscopy (RCM) imaging followed by direct surgical excision
Number of subjects: 95
Study 28391599 — intervention group
Group type: COMPARATOR
Intervention: Standard care (planned excision based on histological diagnosis and subtype of a punch biopsy)
Number of subjects: 95
Study 26336926 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of wild-type p66Shc
Number of subjects: 0
Study 26336926 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of mutant p66Shc (Ala36)
Number of subjects: 0
Study 26336926 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (liver biopsies)
Number of subjects: 0
Study 23381608 — intervention group
Group type: EXPERIMENTAL
Intervention: StO₂ guided resuscitation
Number of subjects: 30
Study 23381608 — intervention group
Group type: COMPARATOR
Intervention: Standard resuscitation without StO₂ guidance
Number of subjects: 30
Study 22573022 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (OT)
Number of subjects: 53
Study 22573022 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 53
Study 20483003 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive craniopuncture combined with urokinase infusion therapy
Number of subjects: 304
Study 20483003 — intervention group
Group type: COMPARATOR
Intervention: Clearance of hematoma by craniotomy with small bone flap
Number of subjects: 304
Study 17509027 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 17509027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 17509027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17509027 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 0
Study 16154019 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES) - Cypher (n=264) and Taxus (n=281)
Number of subjects: 826
Study 16154019 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS) - Vision (n=281)
Number of subjects: 826
Study 16154019 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES) compared to Bare-metal stents (BMS)
Number of subjects: 826
Study 12115091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG) for 10 days
Number of subjects: 38
Study 12115091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (SSG) for 20 days
Number of subjects: 38
Study 10099909 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 15000
Study 10099909 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 15000
Study 7555458 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 85
Study 7555458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 85
Study 7555458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 85
Study 7555458 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (De‐Nol)
Number of subjects: 85
Study 7555458 — intervention group
Group type: COMPARATOR
Intervention: Antacids, Cimetidine, Ranitidine
Number of subjects: 85
Study 2190013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 2,400 mg
Number of subjects: 111
Study 2190013 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B at a daily dose of 1,200 mg
Number of subjects: 111
Study 2190013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 2,400 to 7,200 mg
Number of subjects: 111
Study 2190013 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B at a daily dose of 4,800 mg
Number of subjects: 111
Study 7317219 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic benzylpenicillin and flucloxacillin administered just before operation and one and six hours afterwards.
Number of subjects: 431
Study 7317219 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 431
Study 31835186 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (Males: 0.68 g/kg; Females: 0.60 g/kg)
Number of subjects: 73
Study 31835186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30758295 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive education parenting program (2 phone-based perinatal educational sessions, 1 phone-based educational session after childbirth, 1-month postpartum access to a mobile health app)
Number of subjects: 16
Study 30758295 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hospital care)
Number of subjects: 16
Study 29180855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin ointment
Number of subjects: 20
Study 29180855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25785658 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during transient hyperglycemia for 2 h (visit TH)
Number of subjects: 8
Study 25785658 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during continuous hyperglycemia for 12 h (visit CH)
Number of subjects: 8
Study 25785658 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.5‐1.5 IU/h) as a continuous subcutaneous insulin infusion (CSII) during both visits
Number of subjects: 8
Study 25785658 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 8
Study 24048581 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDT)
Number of subjects: 60
Study 24048581 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional therapy)
Number of subjects: 60
Study 21466532 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus narrowband ultraviolet B (NB-UVB) phototherapy
Number of subjects: 0
Study 21466532 — intervention group
Group type: COMPARATOR
Intervention: Etanercept monotherapy
Number of subjects: 0
Study 21466532 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept plus NB-UVB
Number of subjects: 0
Study 20491143 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative (restrictive) infusion strategy
Number of subjects: 2
Study 20491143 — intervention group
Group type: COMPARATOR
Intervention: Liberal (traditional) infusion strategy
Number of subjects: 2
Study 17298695 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-supplemented yoghurt-like product
Number of subjects: 44
Study 17298695 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 44
Study 14662708 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA infusion at a dose of 0.25 mg ADMA x kg(‐1) x min(‐1)
Number of subjects: 0
Study 14662708 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-nitro-L-arginine methyl ester infusion at a dose of 3 microg x kg(‐1) x min(‐1)
Number of subjects: 0
Study 11703963 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with low-fat foods enriched with 1.25 to 5.0 g/day of nonesterified plant sterols and mineral nutrients (calcium, magnesium, potassium)
Number of subjects: 78
Study 11703963 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with corresponding placebo food items
Number of subjects: 78
Study 9390726 — intervention group
Group type: EXPERIMENTAL
Intervention: R-(+)- and S-(-)-remoxipride
Number of subjects: 0
Study 7911009 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine (8 mg)
Number of subjects: 10
Study 7911009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3309653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (240 mmol per day for 7 days)
Number of subjects: 5
Study 3309653 — intervention group
Group type: COMPARATOR
Intervention: Sodium citrate (equimolar amount to sodium chloride)
Number of subjects: 5
Study 29798795 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 259
Study 29798795 — intervention group
Group type: COMPARATOR
Intervention: Escalated antiarrhythmic drug therapy
Number of subjects: 259
Study 27499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Proretinal nanoparticles
Number of subjects: 0
Study 27499622 — intervention group
Group type: COMPARATOR
Intervention: Retinoic acid (RA)
Number of subjects: 0
Study 27499622 — intervention group
Group type: COMPARATOR
Intervention: Free retinal
Number of subjects: 0
Study 25707921 — intervention group
Group type: COMPARATOR
Intervention: AUSDRISK score group 12-15
Number of subjects: 209
Study 25707921 — intervention group
Group type: EXPERIMENTAL
Intervention: AUSDRISK score group ≥ 20
Number of subjects: 209
Study 25707921 — intervention group
Group type: COMPARATOR
Intervention: Overall sample
Number of subjects: 209
Study 23092785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin plus fibre supplementation (400 mg b.d. for one week per month + 3.5 g high-fibre supplementation b.d.)
Number of subjects: 165
Study 23092785 — intervention group
Group type: COMPARATOR
Intervention: Fibre supplementation alone (3.5 g high-fibre supplementation b.d.)
Number of subjects: 165
Study 23092785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin plus fibre supplementation
Number of subjects: 165
Study 20525840 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 662
Study 20525840 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine 500 mg three times daily
Number of subjects: 662
Study 20525840 — intervention group
Group type: COMPARATOR
Intervention: Combination glucosamine and chondroitin sulphate
Number of subjects: 662
Study 20525840 — intervention group
Group type: COMPARATOR
Intervention: Chondroitin sulphate 400 mg three times daily
Number of subjects: 662
Study 20525840 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 662
Study 18986748 — intervention group
Group type: COMPARATOR
Intervention: Immediate defibrillation
Number of subjects: 202
Study 18986748 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR first
Number of subjects: 202
Study 15631561 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented cardiac rehabilitation and secondary prevention program focusing on lifestyle changes (smoking, diet, exercise, stress); n=46
Number of subjects: 88
Study 15631561 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented cardiac rehabilitation and secondary prevention program; n=46
Number of subjects: 88
Study 15631561 — intervention group
Group type: COMPARATOR
Intervention: Standard-care control group; n=42
Number of subjects: 88
Study 11818769 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 24
Study 11818769 — intervention group
Group type: EXPERIMENTAL
Intervention: R(‐)‐ketamine
Number of subjects: 24
Study 11818769 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine
Number of subjects: 24
Study 10519500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (1.5%)
Number of subjects: 74
Study 10519500 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular saline
Number of subjects: 74
Study 10519500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (250 microg/kg bolus followed by 13 microg x kg(‐1) x h(‐1) infusion)
Number of subjects: 74
Study 10519500 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (equivalent volume to lidocaine)
Number of subjects: 74
Study 7492104 — intervention group
Group type: EXPERIMENTAL
Intervention: A77003 at 0.035 mg/kg/h
Number of subjects: 0
Study 7492104 — intervention group
Group type: EXPERIMENTAL
Intervention: A77003 at 0.07 mg/kg/h
Number of subjects: 0
Study 7492104 — intervention group
Group type: EXPERIMENTAL
Intervention: A77003 at 0.14 mg/kg/h
Number of subjects: 0
Study 7492104 — intervention group
Group type: EXPERIMENTAL
Intervention: A77003 at 0.28 mg/kg/h
Number of subjects: 0
Study 7492104 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 0
Study 1826989 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 186
Study 1826989 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil anesthesia
Number of subjects: 186
Study 6182516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combined preparation (antihistamine + decongestant)
Number of subjects: 80
Study 6182516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31407802 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% G. speciosum ethanolic extract (GSE) serum applied for 56 days
Number of subjects: 24
Study 31407802 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study 30292773 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support for breastfeeding provided by certified and trained promotoras
Number of subjects: 61
Study 30292773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 61